MARKET

DRUG

DRUG

Bright Minds Biosciences Inc
NASDAQ
92.80
+12.79
+15.99%
Opening 14:38 01/06 EST
OPEN
119.80
PREV CLOSE
80.01
HIGH
123.75
LOW
90.62
VOLUME
946.88K
TURNOVER
--
52 WEEK HIGH
123.75
52 WEEK LOW
23.18
MARKET CAP
722.65M
P/E (TTM)
-72.6533
1D
5D
1M
3M
1Y
5Y
1D
BTIG Maintains Buy on Bright Minds Biosciences, Raises Price Target to $147
Benzinga · 4h ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 5h ago
New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday
Benzinga · 5h ago
Bright Minds Biosciences: Robust BMB-101 Phase 2 Data and Clear Registrational Path Underpin $115 Target and Buy Rating
TipRanks · 5h ago
BRIGHT MINDS BIOSCIENCES INC <DRUG.N>: PIPER SANDLER RAISES TARGET PRICE TO $190 FROM $93
Reuters · 6h ago
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday
Benzinga · 7h ago
Bright Minds gains on mid-stage trial win for lead asset
Seeking Alpha · 9h ago
Bright Minds announces results from Phase 2 BREAKTHROUGH trial of BMB-101
TipRanks · 10h ago
More
About DRUG
Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Webull offers Bright Minds Biosciences Inc stock information, including NASDAQ: DRUG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRUG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRUG stock methods without spending real money on the virtual paper trading platform.